Live In Play®
Updated: 19-May-26 15:19 ET
UCBJY:  UCB SA announces BIMZELX demonstrates superior efficacy over AbbVie's (ABBV) SKYRIZI (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data  (135.98 +1.88)
  • BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: 49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 16
  • Improvements in secondary endpoints: Numerically greater responses without statistical significance were observed for BIMZELX vs risankizumab across all secondary endpoints, with no new safety signals observed
  • Greater improvements in joint relief at Week 4: The secondary endpoint of ACR50 at Week 4 was 19.9% for those receiving BIMZELX vs 7.2% for those receiving risankizumab
Cookies are essential for making our site work. By using our site, you consent to the use of these cookies. Read our cookie policy to learn more.
Send
Chat Icon